These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 37185297)

  • 1. CEA dynamics for predicting response after anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer.
    Kang S; Kim SY; Hong YS; Kim TW; Choi KE; Kim MJ; Kim JE
    Sci Rep; 2023 Apr; 13(1):6735. PubMed ID: 37185297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment outcome comparisons of first-line targeted therapy in patients with KRAS wild-type metastatic colorectal cancer: A nationwide database study.
    Liang YH; Chen KH; Shao YY
    Cancer Med; 2023 Jul; 12(14):15176-15186. PubMed ID: 37325970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
    Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
    Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Anti-Epidermal Growth Factor Receptor Therapy Compared with Anti-Vascular Endothelial Growth Factor Therapy for Metastatic Colorectal Cancer: an Update Meta-Analysis of Randomized Clinical Trials.
    Wang JX; Wu HL; Zhu M; Zhou R
    Pathol Oncol Res; 2020 Jan; 26(1):159-166. PubMed ID: 29383654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes.
    Bekaii-Saab TS; Lach K; Hsu LI; Siadak M; Stecher M; Ward J; Beckerman R; Strickler JH
    Oncologist; 2023 Oct; 28(10):885-893. PubMed ID: 37463037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
    Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
    Tol J; Punt CJ
    Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis.
    van Helden EJ; Menke-van der Houven van Oordt CW; Heymans MW; Ket JCF; van den Oord R; Verheul HMW
    Cancer Metastasis Rev; 2017 Jun; 36(2):395-406. PubMed ID: 28695301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Threshold Change in CEA as a Predictor of Non-Progression to First-Line Systemic Therapy in Metastatic Colorectal Cancer Patients With Elevated CEA.
    Gulhati P; Yin J; Pederson L; Schmoll HJ; Hoff P; Douillard JY; Hecht JR; Tournigand C; Tebbut N; Chibaudel B; Gramont A; Shi Q; Overman MJ
    J Natl Cancer Inst; 2020 Nov; 112(11):1127-1136. PubMed ID: 32191317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiepidermal growth factor receptor monoclonal antibody improves survival outcomes in the treatment of patients with metastatic colorectal cancer.
    Wang L; Chen X; Li W; Sheng Z
    Anticancer Drugs; 2012 Feb; 23(2):155-60. PubMed ID: 21955998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer.
    Prager GW; Braemswig KH; Martel A; Unseld M; Heinze G; Brodowicz T; Scheithauer W; Kornek G; Zielinski CC
    Cancer Sci; 2014 Aug; 105(8):996-1001. PubMed ID: 24850362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial.
    Yoshino T; Obermannová R; Bodoky G; Garcia-Carbonero R; Ciuleanu T; Portnoy DC; Kim TW; Hsu Y; Ferry D; Nasroulah F; Tabernero J
    Eur J Cancer; 2017 Jun; 78():61-69. PubMed ID: 28412590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-induction Strategies in Metastatic Colorectal Cancer Patients Treated With First-Line Anti-EGFR-Based Treatment: A Systematic Review and Meta-Analysis.
    Parisi A; Ghidini M; Giampieri R; Tomasello G; Luciani A; Ferri C; Berardi R; Petrelli F
    Clin Colorectal Cancer; 2022 Sep; 21(3):e162-e170. PubMed ID: 35184993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study).
    Palmieri LJ; Mineur L; Tougeron D; Rousseau B; Granger V; Gornet JM; Smith D; Lievre A; Galais MP; Doat S; Pernot S; Bignon-Bretagne AL; Metges JP; Baba-Hamed N; Michel P; Obled S; Vitellius C; Bouche O; Saban-Roche L; Buecher B; des Guetz G; Locher C; Trouilloud I; Goujon G; Dior M; Manfredi S; Soularue E; Phelip JM; Henriques J; Vernery D; Coriat R
    Oncologist; 2020 Feb; 25(2):e266-e275. PubMed ID: 32043796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.
    Arnold D; Lueza B; Douillard JY; Peeters M; Lenz HJ; Venook A; Heinemann V; Van Cutsem E; Pignon JP; Tabernero J; Cervantes A; Ciardiello F
    Ann Oncol; 2017 Aug; 28(8):1713-1729. PubMed ID: 28407110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy.
    Jürgensmeier JM; Schmoll HJ; Robertson JD; Brooks L; Taboada M; Morgan SR; Wilson D; Hoff PM
    Br J Cancer; 2013 Apr; 108(6):1316-23. PubMed ID: 23449351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-EGFR monoclonal antibody plus chemotherapy for treating advanced non-small cell lung cancer: A meta-analysis.
    Luo W; Li Y; Ye F; Li Q; Zhang G; Li J; Li X
    Medicine (Baltimore); 2021 Nov; 100(47):e27954. PubMed ID: 34964780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of use and tolerance of anti-epidermal growth factor receptor antibodies in older adults with metastatic colorectal cancer.
    Dotan E; Devarajan K; D'Silva AJ; Beck A; Kloth DD; Cohen SJ; Denlinger C
    Clin Colorectal Cancer; 2014 Sep; 13(3):192-8. PubMed ID: 25074246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of plasma angiogenesis factors in the efficacy of first-line chemotherapy combined with biologics in RAS wild-type metastatic colorectal cancer: Results from the GI-SCREEN CRC-Ukit study.
    Yuki S; Yamazaki K; Sunakawa Y; Taniguchi H; Bando H; Shiozawa M; Nishina T; Yasui H; Kagawa Y; Takahashi N; Denda T; Esaki T; Kawakami H; Satake H; Takashima A; Matsuhashi N; Kato T; Asano C; Abe Y; Nomura S; Yoshino T
    Cancer Med; 2023 Sep; 12(18):18702-18716. PubMed ID: 37641470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of changes in systemic inflammatory markers and carcinoembryonic antigen levels in predicting metastatic colorectal cancer prognosis and chemotherapy response.
    Kim IH; Lee JE; Yang JH; Jeong JW; Ro S; Lee MA
    Asia Pac J Clin Oncol; 2018 Jun; 14(3):239-246. PubMed ID: 29044941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.